vs

Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.

NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $120.4M, roughly 1.6× Hippo Holdings Inc.). Hippo Holdings Inc. runs the higher net margin — 5.0% vs -57.9%, a 62.8% gap on every dollar of revenue. On growth, Hippo Holdings Inc. posted the faster year-over-year revenue change (18.2% vs 11.1%). Over the past eight quarters, Hippo Holdings Inc.'s revenue compounded faster (18.9% CAGR vs 6.5%).

Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

HIPO vs NEO — Head-to-Head

Bigger by revenue
NEO
NEO
1.6× larger
NEO
$186.7M
$120.4M
HIPO
Growing faster (revenue YoY)
HIPO
HIPO
+7.1% gap
HIPO
18.2%
11.1%
NEO
Higher net margin
HIPO
HIPO
62.8% more per $
HIPO
5.0%
-57.9%
NEO
Faster 2-yr revenue CAGR
HIPO
HIPO
Annualised
HIPO
18.9%
6.5%
NEO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
HIPO
HIPO
NEO
NEO
Revenue
$120.4M
$186.7M
Net Profit
$6.0M
$-108.0M
Gross Margin
43.3%
Operating Margin
5.6%
46.9%
Net Margin
5.0%
-57.9%
Revenue YoY
18.2%
11.1%
Net Profit YoY
-86.4%
42.0%
EPS (diluted)
$0.31
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIPO
HIPO
NEO
NEO
Q1 26
$186.7M
Q4 25
$120.4M
$190.2M
Q3 25
$120.6M
$187.8M
Q2 25
$117.3M
$181.3M
Q1 25
$110.3M
$168.0M
Q4 24
$101.9M
$172.0M
Q3 24
$95.5M
$167.8M
Q2 24
$89.6M
$164.5M
Net Profit
HIPO
HIPO
NEO
NEO
Q1 26
$-108.0M
Q4 25
$6.0M
Q3 25
$98.1M
$-27.1M
Q2 25
$1.3M
$-45.1M
Q1 25
$-47.7M
$-25.9M
Q4 24
$44.2M
Q3 24
$-8.5M
$-17.7M
Q2 24
$-40.5M
$-18.6M
Gross Margin
HIPO
HIPO
NEO
NEO
Q1 26
43.3%
Q4 25
43.8%
Q3 25
42.8%
Q2 25
42.6%
Q1 25
43.6%
Q4 24
44.9%
Q3 24
44.6%
Q2 24
44.1%
Operating Margin
HIPO
HIPO
NEO
NEO
Q1 26
46.9%
Q4 25
5.6%
-7.1%
Q3 25
81.3%
-14.4%
Q2 25
3.4%
-26.3%
Q1 25
-41.3%
-16.6%
Q4 24
46.3%
-10.7%
Q3 24
-5.4%
-12.6%
Q2 24
-40.7%
-13.3%
Net Margin
HIPO
HIPO
NEO
NEO
Q1 26
-57.9%
Q4 25
5.0%
Q3 25
81.3%
-14.4%
Q2 25
1.1%
-24.9%
Q1 25
-43.2%
-15.4%
Q4 24
43.4%
Q3 24
-8.9%
-10.5%
Q2 24
-45.2%
-11.3%
EPS (diluted)
HIPO
HIPO
NEO
NEO
Q1 26
$-0.13
Q4 25
$0.31
Q3 25
$3.77
Q2 25
$0.05
Q1 25
$-1.91
Q4 24
$1.81
Q3 24
$-0.34
Q2 24
$-1.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIPO
HIPO
NEO
NEO
Cash + ST InvestmentsLiquidity on hand
$218.3M
$146.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$436.1M
$828.8M
Total Assets
$1.9B
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIPO
HIPO
NEO
NEO
Q1 26
$146.1M
Q4 25
$218.3M
$159.6M
Q3 25
$247.7M
$164.1M
Q2 25
$198.9M
$154.7M
Q1 25
$140.9M
$346.2M
Q4 24
$197.6M
$367.0M
Q3 24
$191.2M
$362.0M
Q2 24
$175.9M
$355.1M
Total Debt
HIPO
HIPO
NEO
NEO
Q1 26
Q4 25
$341.9M
Q3 25
Q2 25
Q1 25
Q4 24
$541.1M
Q3 24
Q2 24
Stockholders' Equity
HIPO
HIPO
NEO
NEO
Q1 26
$828.8M
Q4 25
$436.1M
$836.6M
Q3 25
$421.5M
$838.3M
Q2 25
$332.5M
$854.0M
Q1 25
$322.8M
$888.3M
Q4 24
$362.1M
$902.3M
Q3 24
$326.4M
$908.2M
Q2 24
$322.6M
$915.9M
Total Assets
HIPO
HIPO
NEO
NEO
Q1 26
$1.3B
Q4 25
$1.9B
$1.4B
Q3 25
$1.9B
$1.4B
Q2 25
$1.7B
$1.4B
Q1 25
$1.5B
$1.6B
Q4 24
$1.5B
$1.6B
Q3 24
$1.5B
$1.6B
Q2 24
$1.5B
$1.6B
Debt / Equity
HIPO
HIPO
NEO
NEO
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIPO
HIPO
NEO
NEO
Operating Cash FlowLast quarter
$9.2M
$-8.1M
Free Cash FlowOCF − Capex
$9.1M
FCF MarginFCF / Revenue
7.6%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.53×
TTM Free Cash FlowTrailing 4 quarters
$14.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIPO
HIPO
NEO
NEO
Q1 26
$-8.1M
Q4 25
$9.2M
$1.3M
Q3 25
$16.9M
$8.9M
Q2 25
$24.7M
$20.3M
Q1 25
$-35.6M
$-25.3M
Q4 24
$47.5M
$9.8M
Q3 24
$46.8M
$9.2M
Q2 24
$-10.6M
$13.9M
Free Cash Flow
HIPO
HIPO
NEO
NEO
Q1 26
Q4 25
$9.1M
$-6.5M
Q3 25
$16.8M
$570.0K
Q2 25
$24.6M
$14.0M
Q1 25
$-35.7M
$-29.8M
Q4 24
$47.2M
$-1.8M
Q3 24
$-1.6M
Q2 24
$-10.7M
$814.0K
FCF Margin
HIPO
HIPO
NEO
NEO
Q1 26
Q4 25
7.6%
-3.4%
Q3 25
13.9%
0.3%
Q2 25
21.0%
7.7%
Q1 25
-32.4%
-17.8%
Q4 24
46.3%
-1.0%
Q3 24
-0.9%
Q2 24
-11.9%
0.5%
Capex Intensity
HIPO
HIPO
NEO
NEO
Q1 26
Q4 25
0.1%
4.1%
Q3 25
0.1%
4.4%
Q2 25
0.1%
3.5%
Q1 25
0.1%
2.7%
Q4 24
0.3%
6.7%
Q3 24
0.0%
6.4%
Q2 24
0.1%
8.0%
Cash Conversion
HIPO
HIPO
NEO
NEO
Q1 26
Q4 25
1.53×
Q3 25
0.17×
Q2 25
19.00×
Q1 25
Q4 24
1.07×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons